Table of Contents

company-logo

Iovance Biotherapeutics, Inc., a clinical-stage biotechnology company, focuses on developing and commercializing cancer immunotherapy products to harness the power of a patient's immune system to eradicate cancer cells. It has six ongoing phase 2 clinical studies, including C-144-01, of its lead product candidate, lifileucel, for the treatment of metastatic melanoma; C-145-04, of its product candidate lifileucel for recurrent, metastatic, or persistent cervical cancer; and C-145-03, of its product candidate LN-145, for recurrent and/or metastatic head and neck squamous cell carcinoma. Iovance Biotherapeutics, Inc. has collaborations and licensing agreements with H. Lee Moffitt Cancer Center; M.D. Anderson Cancer Center; Ohio State University; Centre hospitalier de l'Université de Montreal; Cellectis S.A.; and Novartis Pharma AG. The company was formerly known as Lion Biotechnologies, Inc. and changed its name to Iovance Biotherapeutics, Inc. in June 2017. Iovance Biotherapeutics, Inc. was incorporated in 2007 and is headquartered in San Carlos, California.

Iovance Biotherapeutics Dividend Announcement

• Iovance Biotherapeutics does not currently offer dividends, we're keeping a close eye on its growth potential and financial developments.
• Stay tuned for updates on Iovance Biotherapeutics dividend policy and future announcements. In the meantime, explore other dividend-yielding opportunities on our website.

Iovance Biotherapeutics Dividend History

Iovance Biotherapeutics Dividend Yield

Iovance Biotherapeutics current trailing twelve-month (TTM) dividend yield is -%. Interested in purchasing Iovance Biotherapeutics stock? Use our calculator to estimate your expected dividend yield:

Iovance Biotherapeutics Financial Ratios

P/E ratio-6.61
PEG ratio0.30
P/B ratio3.51
ROE-58.43%
Payout ratio0.00%
Current ratio4.22
Quick ratio3.90
Cash Ratio1.39

Iovance Biotherapeutics Dividend FAQ

Does Iovance Biotherapeutics stock pay dividends?
Iovance Biotherapeutics does not currently pay dividends to its shareholders.
Has Iovance Biotherapeutics ever paid a dividend?
No, Iovance Biotherapeutics has no a history of paying dividends to its shareholders. Iovance Biotherapeutics is not known for its dividend payments.
Why doesn't Iovance Biotherapeutics pay dividends?
There are several potential reasons why Iovance Biotherapeutics would choose not to pay dividends to their shareholders:

1. Growth opportunities: Companies, especially in fast-growing industries like technology, reinvest earnings into expansion, R&D, or acquisitions to fuel future growth and increase company value.

2. Tax implications: Not paying dividends can reduce the tax burden on shareholders, who may prefer to defer taxes until selling shares and realizing capital gains.

3. Investor preferences: Some investors prefer companies to reinvest profits for higher long-term returns, particularly those seeking capital appreciation over income.

4. Capital allocation priorities: Companies may allocate cash to pay down debt, fund share buybacks, or invest in projects with higher returns than dividends.

5. Market expectations: In certain sectors, like technology, reinvesting profits for growth and innovation is often prioritized over distributing dividends to shareholders.
Will Iovance Biotherapeutics ever pay a dividend?
The decision for a company to pay dividends depends on various factors including its financial performance, growth prospects, capital allocation priorities, and shareholder preferences. While Iovance Biotherapeutics has not paid dividends historically and has instead focused on reinvesting its earnings for growth, it's ultimately up to the company's management and board of directors to decide whether to initiate a dividend policy in the future.
Is Iovance Biotherapeutics a dividend aristocrat?
Iovance Biotherapeutics is not considered a Dividend Aristocrat. The term "Dividend Aristocrat" is typically used to describe a company in the S&P 500 index that has increased its dividend payouts for at least 25 consecutive years.
Is Iovance Biotherapeutics a dividend king?
Iovance Biotherapeutics is not classified as a "Dividend King". A Dividend King is a company that has managed to increase its dividend payouts for 50 consecutive years or more, which is an even more selective group than the Dividend Aristocrats.
Is Iovance Biotherapeutics a dividend stock?
No, Iovance Biotherapeutics is not considered a dividend stock. A dividend stock is a stock of a company that regularly pays out dividends to its shareholders.
How to buy Iovance Biotherapeutics stocks?
To buy Iovance Biotherapeutics you need a brokerage account. Open an account with a reputable brokerage firm that offers access to the stock market. Consider factors such as fees and account minimums.

Place an order: Use the brokerage's trading platform to place an order to buy Iovance Biotherapeutics stock.

Remember that buying stocks involves risk, and it's important to carefully consider your investment goals, risk tolerance, and conduct thorough research before making any investment decisions.